


Based on Form PTO-1449 (3/90)				ATTY. DOCKET NO. 671308-2001		SERIAL NO. 10/782,899	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) AUG 23 2004 PATENT & TRADEMARK OFFICE				APPLICANT Minoru FUJIMORI et al			
				FILING DATE February 23, 2004		GROUP 1635	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BY	AA	4,486,407	02-1983	Taguchi	424	85	
	AB	2002-0006432 A1	07-2001	Collins et al.	424	489	
	AC	6,416,754	7/2002	Brown et al.			
	AD	2002/0182229	12/2002	Brown et al.			
BL	AE	2003/0103952	6/2003	Brown et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
BL	AF	WO 96/11277	10/1995	WIPO			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
AL	AG	M J Lemmon et al., "Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment", Gene Therapy, Vol. 4, 1997, pp. 791-796.					
	AH	N. Minton et al., "Chemotherapeutic tumor targeting using clostridial spores", FEMS Microbiology Reviews, Vol. 17, 1995, pp. 357-364					
	AI	Proceedings, Fifty-Ninth Annual Meeting of the Japanese Cancer Association, October 4-6, 2000, Yokohama, Vo. 91 Supplement, No. 1880 as well as its English translation and Verification of translation.					
	AJ	Yazawa et al., Cancer Gene Therapy, Vol. 17, pp. 269-274 published on March 27, 2000 as well as a copy of the certificate. <del>K. Low et al., "Lipid A mutant <i>Salmonella</i> with suppressed virulence and TNF<math>\alpha</math> induction retain tumor-targeting <i>in vivo</i>", Nature Biotechnology, Vol. 17, January 1999, pp. 37-41.</del>					
	AK	K. Low et al., "Lipid A mutant <i>Salmonella</i> with suppressed virulence and TNF $\alpha$ induction retain tumor-targeting <i>in vivo</i> ", Nature Biotechnology, Vol. 17, January 1999, pp. 37-41					
BL	AL	G. Dachs et al., "Targeting gene expression to hypoxic tumor cells", Nature Medicine, Vol. 3, No. 5, May 1997, pp. 515-520.					
EXAMINER [Signature]				DATE CONSIDERED 7/12/01			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Based on Form PTO-1449 (3/90)		ATTY. DOCKET NO. 671308-2001	SERIAL NO. 10/782,899
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Minoru FUJIMORI et al	
		FILING DATE February 23, 2004	GROUP 1635
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
PY	AM	H. Matsumura et al., "Construction of <i>Escherichia coli</i> - <i>Bifidobacterium longum</i> shuttle vector transforming <i>B. longum</i> 105-A and 108-A", Biosci. Biotech. Biochem., Vol. 61, No. 7, 1997, pp. 1211-1212.	
	AN	A. Argnani et al., "A convenient and reproducible method to genetically transform bacteria of the genus <i>Bifidobacterium</i> ", Microbiology, Vol. 142, 1996, pp. 109-114.	
	AO	N. Kimura et al., "Selective localization and growth of <i>Bifidobacterium bifidum</i> in mouse tumors following intravenous administration", Cancer Research, Vol. 40, June 1980, pp. 2061-2068.	
	AP	M. Fox et al., "Anaerobic bacteria as a delivery system for cancer gene therapy: <i>in vitro</i> activation of 5-fluorocytosine by genetically engineered clostridia", Gene Therapy, Vol. 3, 1996, pp. 173-178.	
	AQ	C. Tacket et al., "Comparison of the Safety and Immunogenicity of $\Delta$ aroC $\Delta$ aroD and $\Delta$ cya $\Delta$ crp <i>Salmonella typhi</i> Strains in Adult Volunteers", Infection and Immunity, Vol. 60, No. 2, pp. 536-541, February 1992.	
	AR	H. Yasui et al., "Enhancement of Immune Response in Peyer's Patch Cells Cultured with <i>Bifidobacterium breve</i> ", Journal of Dairy Science, Vol. 74, pp. 1187-1195, 1991.	
	AS	D. Salzman et al., "Attenuated <i>Salmonella typhimurium</i> Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor Agent", Cancer Biotherapy and Radiopharmaceuticals, Vol. 11, No. 2, pp. 145-153, 1996.	
	AT	J. Saavedra et al., "Feeding of <i>Bifidobacterium bifidum</i> and <i>Streptococcus thermophilus</i> to Infants in Hospital for Prevention of Diarrhoea and Shedding of Rotavirus", The Lancet, Vol. 344, pp. 1046-1049, October 15, 1994	
	AU	B. Reddy et al., "Inhibitory Effect of <i>Bifidobacterium longum</i> on Colon, Mannary, and Liver Carcinogenesis Induced by 2-Amino-3-methylimidazo[4,5-f]quinoline, a Food Mutagen", Cancer Research, Vol. 53, pp. 3914-3918, September 1, 1993.	
	AV	D. Hone et al., "Evaluation in Volunteers of a Candidate Live Oral Attenuated <i>Salmonella typhi</i> Vector Vaccine", Journal of Clinical Investigation, Vol. 90, pp. 412-420, 1992.	
	AW	M. Babincova et al., Life and medical Sciences Online, (2000), 1, pp. 1-4.	
	AX	IM Verma et al., Nature, "Gene therapy-promises, problems and prospects," Sep. 1997, Vol. 389, pp. 239-242.	
	AY	WF Anderson, Nature, "Human gene therapy", Apr. 1998, Vol. 392, pp. 25-30.	
PZ	AZ	K Yazawa et al., Breast Cancer Research and Treatment, "Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors," 2001, 66, pp. 156-170.	
EXAMINER Pina d. Llanos		DATE CONSIDERED 7/28/01	
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Based on Form PTO-1449 (3/90)		ATTY. DOCKET NO.  <div style="text-align: center;">671308-2001.1</div>		SERIAL NO.  <div style="text-align: center;">10/782,899</div>	
<div style="text-align: center;">  </div> REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT  <div style="text-align: center;">Minoru FUJIMORI et al.</div>			
		FILING DATE  <div style="text-align: center;">February 23, 2004</div>		GROUP  <div style="text-align: center;">1632 1635</div>	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	* 6,416,754	7/2002	Brown et al.			
	AB	* 2002/018229	12/2002	Brown et al.			
	AC	* 2003/0103952	6/2003	Brown et al.			
	AD	* 4,480,407	2/1983	Taguchi	424	85	
	AE	* 2002/0006432	7/2001	Collins et al.	424	430	
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BW	AL	98111517	09/30/98	JAPAN			Abstract	
	AM	* WO 98/11277	10/1995	WIPO				
	AN							
	AO							
	AP							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
BW	AQ		Els Kievit et al.: "Superiority of Yeast over Bacterial Cytosine Deaminase for Enzyme/Prodrug Gene Therapy in Colon Cancer Xenografts," (Cancer Research 59 1417-1421, April 1, 1999)
	AR		* K. Low et al., "Lipid A mutant <i>Salmonella</i> with suppressed virulence and TNF $\alpha$ induction retain tumor-targeting <i>in vivo</i> ", Nature Biotechnology, Vol. 17, Jan 1999, pp. 37-41.
	AS		* G. Doehn et al., "Targeting gene expression to hypoxic tumor cells", Nature Medicine, Vol. 3, No. 5, May 1997, pp. 515-520.
	AT		* H. Matsumura et al., "Construction of <i>Escherichia coli-Bifidobacterium longum</i> shuttle vector transforming <i>B. longum</i> 105-A and 106-A", Biocell Biochem, Vol. 61, No. 7, 1997, pp. 1211-1212.
	AU		* A. Argenti et al., "A convenient and reproducible method to genetically transform bacteria of the genus <i>Bifidobacterium</i> ", Microbiology, Vol. 142, 1996, pp. 109-114.

EXAMINER  <div style="text-align: center; font-size: 1.5em;">BW 1 LA</div>	DATE CONSIDERED  <div style="text-align: center; font-size: 1.5em;">7/24/01</div>
--	---

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449 (3/90)		ATTY. DOCKET NO.  <div style="text-align: center;">671308-2001.1</div>	SERIAL NO.  <div style="text-align: center;">10/782,899</div>
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT  <div style="text-align: center;">Minoru FUJIMORI et al.</div>	
		FILING DATE  <div style="text-align: center;">February 23, 2004</div>	GROUP  <div style="text-align: center;">1632-1635</div>
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
AV		<del>* N. Kimura et al., "Selective localization and growth of <i>Bifidobacterium bifidum</i> in mouse tumors following intravenous administration", Cancer Research, Vol. 40, June 1980, pp. 2061-2068.</del>	
AW		<del>* M. Fox et al., "Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia", Gene Therapy, Vol. 3, 1996, pp. 173-178.</del>	
AX		<del>* MJ Lemmon et al., "Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment", Gene Therapy, Vol. 4, 1997, pp. 791-796.</del>	
AY		<del>* N. Minton et al., "Chemotherapeutic tumour targeting using clostridial spores", FEMS Microbiology Reviews, Vol. 17, 1993, pp. 337-364.</del>	
AZ		<del>* Proceedings, Fifty-Ninth Annual Meeting of the Japanese Cancer Association, October 4-6, 2000, Yokohama, Vol. 91 Supplement, No. 1880 as well as its English translation and Verification of translation.</del>	
BA		<del>* Yawawa et al., Cancer Gene Therapy, Vol. 7, pp. 209-214 published on March 27, 2000 as well as a copy of the certificate.</del>	
BB		<del>* C. Tacket et al., "Comparison of the Safety and Immunogenicity of ΔaroC ΔaroD and Δcya Δcrp <i>Salmonella typhi</i> Strains in Adult Volunteers", Infection and Immunity, Vol. 60, No. 2, pp. 536-541, Feb. 1992.</del>	
BC		<del>* H. Yasui et al., "Enhancement of Immune Responses in Peyer's Patch Cells Cultured with <i>Bifidobacterium breve</i>", Journal of Dairy Science, Vol. 74, pp. 1187-1195, 1991.</del>	
BD		<del>* D. Saltzman et al., "Attenuated <i>Salmonella typhimurium</i> Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor Agent", Cancer Biotherapy and Radiopharmaceuticals, Vol. 11, No. 2, pp. 145-153, 1996.</del>	
BE		<del>* J. Saavedra et al., "Feeding of <i>Bifidobacterium bifidum</i> and <i>Streptococcus thermophilus</i> to Infants in Hospital for Prevention of Diarrhoea and Shedding of Rotavirus", The Lancet, Vol. 344, pp. 1046-1049, Oct. 15, 1994.</del>	
BF		<del>* B. Reddy et al., "Inhibitory Effect of <i>Bifidobacterium longum</i> on Colon, Mammary, and Liver Carcinogenesis Induced by 2-Amino-3-methylimidazo[4,5-f]quinoline, a Food Mutagen", Cancer Research, Vol. 53, pp. 3914-3919, Sep 1, 1993.</del>	
BG		<del>* D. Hone et al., "Evaluation in Volunteers of a Candidate Live Oral Attenuated <i>Salmonella typhi</i> Vector Vaccine", Journal of Clinical Investigation, Vol. 90, pp. 412-420, 1992.</del>	
BH		<del>* M. Babincova et al., Life and Medical Sciences Online, (2000), 1, pp. 1-4.</del>	
BI		<del>* IM Verma et al., Nature, "Gene therapy promises, problems and prospects," Sep. 1992, Vol. 359, pp. 239-242.</del>	
BJ		<del>* WE Anderson, Nature, "Human gene therapy," Apr. 1998, Vol. 392, pp. 25-30.</del>	
BK		<del>* K. Yawawa et al., Breast Cancer Research and Treatment, "<i>Bifidobacterium longum</i> as a delivery system for gene therapy of chemically induced rat mammary tumors," 2001, 66, pp. 165-170.</del>	
BL			
BM			
BN			
BO			
BP			
BQ			
EXAMINER <div style="font-size: 1.5em; font-family: cursive;">D. L. H.</div>		DATE CONSIDERED <div style="font-size: 1.5em; font-family: cursive;">7/27/01</div>	
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			